Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTGel/ BPO Wash · 1 trial · 1 indication
Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application. Grading will use the following scale: 0 - None 1. \- Trace 2. \- Mild 3. \- Moderate 4. \- Marked 5. \- Severe
Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application. Grading will use the following scale: 0 - None 1. \- Trace 2. \- Mild 3. \- Moderate 4. \- Marked 5. \- Severe
Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application. Grading will use the following scale: 0 - None 1. \- Trace 2. \- Mild 3. \- Moderate 4. \- Marked 5. \- Severe
| Arm | Type | Description |
|---|---|---|
| CTGel plus BPO wash | EXPERIMENTAL | Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening |
| CTGel | ACTIVE_COMPARATOR | Soap Free Cleanser in the morning and CTGel in the evening |
| Name | Type | Description |
|---|---|---|
| CTGel/ BPO Wash | DRUG | Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days. |
| Soap Free Cleanser and CTGel | DRUG | Soap Free Cleanser will be used once daily in the morning for 28 days Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days. |
Inclusion Criteria: * Subjects with mild to moderate facial acne vulgaris, with no history of known or suspected hypersensitivity or previous allergic reaction to any of the ingredients of the study products (eg, topical antibiotics, retinoids or benzoyl peroxide), capable of understanding and will...
CTGel/ BPO Wash is used for the treatment of acne vulgaris, a common skin condition characterized by pimples, blackheads, and whiteheads. It is a topical combination regimen being developed by GSK plc for dermatology applications. The drug is currently in Phase 3 clinical development.
CTGel/ BPO Wash is a small molecule topical treatment for acne vulgaris. While the specific molecular targets are not disclosed, it combines an antibiotic and a retinoid with a benzoyl peroxide (BPO) wash. This regimen is designed to address acne through multiple mechanisms, including antibacterial and skin cell turnover effects.
CTGel/ BPO Wash is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate the safety and efficacy of this topical treatment for acne vulgaris.
CTGel/ BPO Wash is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the results will inform potential regulatory submissions for the treatment of acne vulgaris.
CTGel/ BPO Wash has one completed Phase 3 clinical trial, identified as NCT00891982. This study evaluated the tolerability of a topical antibiotic and retinoid used in a combined regimen with a BPO wash in 60 patients with acne vulgaris. The trial was conducted in the United States and enrolled participants aged 12 years and older.
CTGel/ BPO Wash is a specific combination regimen developed by GSK plc. It combines a topical antibiotic and retinoid with a benzoyl peroxide wash, which are common ingredients in acne treatments. However, the specific formulation and combination are unique to this investigational drug, and it is not marketed under any other names.